[
  {
    "ts": "2025-11-24T12:45:00+00:00",
    "headline": "RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum",
    "summary": "RVL Pharmaceuticals, Inc and its affiliates (together, \"RVL\") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.",
    "url": "https://finance.yahoo.com/news/rvl-pharmaceuticals-announces-leadership-appointments-124500429.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "1d8d0747-1d94-3b4e-9c56-5bb146867a46",
      "content": {
        "id": "1d8d0747-1d94-3b4e-9c56-5bb146867a46",
        "contentType": "STORY",
        "title": "RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum",
        "description": "",
        "summary": "RVL Pharmaceuticals, Inc and its affiliates (together, \"RVL\") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.",
        "pubDate": "2025-11-24T12:45:00Z",
        "displayTime": "2025-11-24T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/80efeb6a95ce099da2d60c9bf9629f50",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Rc80fgTAsLDaU9xn4TeSqQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/80efeb6a95ce099da2d60c9bf9629f50.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VZWM2VsT7coc_hFN.xjnzg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/80efeb6a95ce099da2d60c9bf9629f50.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rvl-pharmaceuticals-announces-leadership-appointments-124500429.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rvl-pharmaceuticals-announces-leadership-appointments-124500429.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVLPQ"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-24T12:00:00+00:00",
    "headline": "Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)",
    "summary": "NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is b",
    "url": "https://finance.yahoo.com/news/arvinas-announces-data-presentations-vepdegestrant-120000255.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "ab841ed7-137e-3a59-83b7-3eff8b5c40b6",
      "content": {
        "id": "ab841ed7-137e-3a59-83b7-3eff8b5c40b6",
        "contentType": "STORY",
        "title": "Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)",
        "description": "",
        "summary": "NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is b",
        "pubDate": "2025-11-24T12:00:00Z",
        "displayTime": "2025-11-24T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081",
          "originalWidth": 696,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yh2mtJa2t7nTvrtnMIWuQQ--~B/aD0yNTI7dz02OTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081.cf.webp",
              "width": 696,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zGbLsZv8o._cDdc.ul0VDA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/arvinas-announces-data-presentations-vepdegestrant-120000255.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/arvinas-announces-data-presentations-vepdegestrant-120000255.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ARVN"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-24T13:16:00+00:00",
    "headline": "Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally",
    "summary": "LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.",
    "url": "https://finance.yahoo.com/news/lilly-crosses-1-trillion-market-131600200.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "54568140-3315-39dc-a988-989183abe3a5",
      "content": {
        "id": "54568140-3315-39dc-a988-989183abe3a5",
        "contentType": "STORY",
        "title": "Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally",
        "description": "",
        "summary": "LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.",
        "pubDate": "2025-11-24T13:16:00Z",
        "displayTime": "2025-11-24T13:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-crosses-1-trillion-market-131600200.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-crosses-1-trillion-market-131600200.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-24T15:37:00+00:00",
    "headline": "Urinary Tract Infection Treatment Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue",
    "summary": "The Urinary Tract Infection (UTI) Treatment Market is projected to grow from US$ 9.13 Billion in 2024 to US$ 11.64 Billion by 2033, at a CAGR of 2.73%. This expansion is driven by rising UTI prevalence, awareness of early diagnosis, and advancements in therapy. Key growth factors include aging populations, rising catheter-associated infections, and a growing female demographic. Innovative treatments like vaccines and probiotics are gaining traction amid antibiotic resistance. North America leads",
    "url": "https://finance.yahoo.com/news/urinary-tract-infection-treatment-market-153700241.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "cea92379-fe35-3dfa-b097-16f3bb258ff6",
      "content": {
        "id": "cea92379-fe35-3dfa-b097-16f3bb258ff6",
        "contentType": "STORY",
        "title": "Urinary Tract Infection Treatment Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue",
        "description": "",
        "summary": "The Urinary Tract Infection (UTI) Treatment Market is projected to grow from US$ 9.13 Billion in 2024 to US$ 11.64 Billion by 2033, at a CAGR of 2.73%. This expansion is driven by rising UTI prevalence, awareness of early diagnosis, and advancements in therapy. Key growth factors include aging populations, rising catheter-associated infections, and a growing female demographic. Innovative treatments like vaccines and probiotics are gaining traction amid antibiotic resistance. North America leads",
        "pubDate": "2025-11-24T15:37:00Z",
        "displayTime": "2025-11-24T15:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/38cc98cd824149bb5e93366f731ac3e5",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Urinary Tract Infection Treatment Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NCf4uWgMkd0SvYLsuJCskw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/38cc98cd824149bb5e93366f731ac3e5.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7l0R6p6DoqBE1d2lYgU_4g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/38cc98cd824149bb5e93366f731ac3e5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/urinary-tract-infection-treatment-market-153700241.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/urinary-tract-infection-treatment-market-153700241.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-24T15:26:06+00:00",
    "headline": "Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer",
    "summary": "Bayer issued a \"surprisingly positive\" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.",
    "url": "https://www.investors.com/news/technology/bristol-myers-squibb-bayer-blood-thinner-stroke-prevention/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "df9fca1e-354d-31a9-8f72-eac349ab0c28",
      "content": {
        "id": "df9fca1e-354d-31a9-8f72-eac349ab0c28",
        "contentType": "STORY",
        "title": "Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer",
        "description": "",
        "summary": "Bayer issued a \"surprisingly positive\" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.",
        "pubDate": "2025-11-24T15:26:06Z",
        "displayTime": "2025-11-24T15:26:06Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/df9fca1e-354d-31a9-8f72-eac349ab0c28/bristol-myers-pops-on-a.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/c86151a606376a1cfc78202e4a0ae9c6",
          "originalWidth": 1065,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NeOF0cSwj3KGn_S6VqRFZg--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/c86151a606376a1cfc78202e4a0ae9c6.cf.webp",
              "width": 1065,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0Ds.YjvX7WM0a9KWl38jIQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/c86151a606376a1cfc78202e4a0ae9c6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/bristol-myers-squibb-bayer-blood-thinner-stroke-prevention/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYN.DE"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]